Neurology Market: A BCC Research Overview
REPORT SCOPE:
The scope of this report is broad and covers therapeutics used in treatment of neurological disorders.
The report highlights the current and future market potential of neurology medicines and provides a detailed analysis of the competitive environment, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The report details market shares of neurology based on different disease indication. Based on neurological disorders the market is segmented into Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases. Each diseases segment covers therapeutics and regional analysis.
The market of Parkinson Diseases covers anti-Parkinson’s drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into dopaminergic, enzyme inhibitors, dopamine agonists and other Anti-Parkinson’s medications. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Alzheimer Diseases covers anti-Alzheimer drugs. the market is segmented based on mechanism of action of drugs and region. based on drug class the market is segmented into AChE inhibitors and NMDA antagonist. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of psychotic diseases covers antipsychotic drugs. The market is segmented into drug class and region. Based on drug, the market is segmented into D2 antagonists, D2/5HT2A antagonists, and D2 partial agonist. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Epileptic Diseases covers Anti-Epileptic Drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into first generation drugs, second generation drugs, and third generation drugs. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of autism disorder covers autism disorder therapeutics. The market is segmented into drug based on labelled information and region. Based on drug class the market is segmented into ASD-labeled pharmaceuticals and Off-label pharmaceuticals. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of brain tumor covers brain tumor therapeutics. The market is segmented into therapy type and region. Based on therapy type, the market is segmented into chemotherapy and targeted therapy. Based on region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.
For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
REPORT INCLUDES:
The scope of this report is broad and covers therapeutics used in treatment of neurological disorders.
The report highlights the current and future market potential of neurology medicines and provides a detailed analysis of the competitive environment, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The report details market shares of neurology based on different disease indication. Based on neurological disorders the market is segmented into Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases. Each diseases segment covers therapeutics and regional analysis.
The market of Parkinson Diseases covers anti-Parkinson’s drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into dopaminergic, enzyme inhibitors, dopamine agonists and other Anti-Parkinson’s medications. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Alzheimer Diseases covers anti-Alzheimer drugs. the market is segmented based on mechanism of action of drugs and region. based on drug class the market is segmented into AChE inhibitors and NMDA antagonist. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of psychotic diseases covers antipsychotic drugs. The market is segmented into drug class and region. Based on drug, the market is segmented into D2 antagonists, D2/5HT2A antagonists, and D2 partial agonist. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Epileptic Diseases covers Anti-Epileptic Drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into first generation drugs, second generation drugs, and third generation drugs. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of autism disorder covers autism disorder therapeutics. The market is segmented into drug based on labelled information and region. Based on drug class the market is segmented into ASD-labeled pharmaceuticals and Off-label pharmaceuticals. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of brain tumor covers brain tumor therapeutics. The market is segmented into therapy type and region. Based on therapy type, the market is segmented into chemotherapy and targeted therapy. Based on region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.
For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
REPORT INCLUDES:
- 15 data tables and 22 additional tables
- An in-depth overview and industry analysis of the global market for neurology medicines
- Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Historical background on neurological disorders and therapeutics, growing prevalence of neurological disorders, increasing research and development activities regarding neurology research, and analysis of the factors influencing the market
- Quantitative analysis of the neurology therapeutics market covering Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases
- Discussion of various therapeutics used for treatment of different neurological disorders, along with coverage of novel pipeline, patent expiry of blockbuster drug and new drug approvals
- Reviews of the competitive landscape, key strategies adopted by market players, mergers and acquisitions details, pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage etc.
- Details company profile of leading participants within the neurology market including, AbbVie, Biogen, GlaxoSmithKline Plc, Johnson & Johnson, and Sun Pharmaceuticals Industries Ltd.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Neurological Disorders: Overview
Disease Background
Parkinson Disease
Alzheimer Disease
Schizophrenia
Bipolar Disorders
Depression
Epileptic Disorders
Autism Spectrum Disorders
Neuroprotective Agents
Neuroprotective Strategies
Drug Development Regulations
U.S.
Canada
Mexico
Europe
Asia-Pacific
ROW
Reimbursement Landscape
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Government and NGO Initiatives in Creating Awareness
Growing Geriatric Population with Neurological Disorders
Increasing Global Incidence of Neurological Disorders
Research Initiatives in Neurology
Accelerated Approvals for Drugs Used in Rare Diseases
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
Adverse Side Effects
High Cost of Drug Development
CHAPTER 5 GLOBAL MARKET FOR NEUROLOGY
Global Market for Neurology, by Disease Indication
CHAPTER 6 GLOBAL MARKET FOR PARKINSON DISEASE
Anti-Parkinson’s Drugs: Market Overview
Anti-Parkinson’s Drugs Market, by Drug Class
Dopaminergic
Market Size and Forecast
Market Analysis
Dopamine Agonists
Market Size and Forecast
Market Analysis
Enzyme Inhibitors Market
Market Size and Forecast
Market Analysis
Other Anti-Parkinson’s Drugs
Market Size and Forecast
Market Analysis
Anti-Parkinson’s Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
Global Company Share Analysis
CHAPTER 7 GLOBAL MARKET FOR ALZHEIMER DISEASE
Market Overview
Global Alzheimer Drugs Market, by Mechanism of Action
AChEIs
Market Size and Forecast
Market Analysis
NMDA Drugs
Market Size and Forecast
Market Analysis
Global Alzheimer Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Rest of the World
Market Size and Forecast
Market Analysis
Industry Structure
Impact of Generic AD Therapeutics
CHAPTER 8 GLOBAL MARKET FOR PSYCHOTIC DISORDERS
Market Overview
Global Antipsychotic Drugs Market, by Drug Class
D2 Antagonists
Market Size and Forecast
Market Analysis
D2/5HT2A Antagonists
Market Size and Forecast
Market Analysis
D2 Partial Agonists
Market Size and Forecast
Market Analysis
Global Antipsychotic Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
Global Company Share Analysis
Impact of Generic Antipsychotic Drugs on the Market
CHAPTER 9 GLOBAL MARKET FOR EPILEPTIC DISORDERS
Market Overview
Market Trends
Global Anti-Epileptic Drugs Market, by Drug Class
First Generation Anti-Epileptic Drugs
Market Size and Forecast
Market Analysis
Second Generation Anti-Epileptic Drugs
Market Size and Forecast
Market Analysis
Third Generation Anti-Epileptic Drugs
Market Size and Forecast
Market Analysis
Global Anti-Epileptic Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
Anti-Epileptic Drugs Market Competitive Landscape
CHAPTER 10 GLOBAL MARKET FOR AUTISM SPECTRUM DISORDERS
Market Overview
Antipsychotics
Antidepressants
Stimulants
Anticonvulsants
Global ASD Therapeutics Market, by Label Information
Labeled ASD Pharmaceuticals
Market Size and Forecast
Market Analysis
Off-label Pharmaceuticals
Market Size and Forecast
Market Analysis
Global ASD Therapeutics Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Rest of the World
Market Size and Forecast
Market Analysis
Global ASD Therapeutics Market Industry Structure
CHAPTER 11 GLOBAL MARKET FOR BRAIN TUMOR THERAPEUTICS
Market Overview
Brain Tumor Therapeutics Market, by Therapy Type
Chemotherapy
Market Size and Forecast
Market Analysis
Targeted Therapy
Market Size and Forecast
Market Analysis
Immunotherapy
Immunotherapeutic Agents
New Developments
Brain Tumor Therapeutics Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
Rest of the World
Market Size and Forecast
Market Analysis
Company Share Analysis
CHAPTER 12 PIPELINE ANALYSIS
Overview of the Drug Development Process
CHAPTER 13 COMPETITIVE LANDSCAPE
Key Strategies Adopted by Market Players
Mergers and Acquisitions
Agreements and New Product Launches
CHAPTER 14 COMPANY PROFILES
ABBVIE
ACADIA PHARMACEUTICALS, INC.
ALEMBIC PHARMACEUTICALS LTD.
ALEXZA PHARMACEUTICALS
ALKERMES PLC
ALLERGAN PLC
APOTEX, INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
AUTISM THERAPEUTICS
AVANIR PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB CO.
BIOGEN
DAIICHI SANKYO CO., LTD.
DR. REDDY’S LABORATORIES LTD.
ELI LILLY AND CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GEDEON RICHTER PLC
IMMUNOCELLULAR THERAPEUTICS, LTD.
JOHNSON & JOHNSON
LANNETT CO., INC.
H. LUNDBECK A/S
LUPIN LTD.
MALLINCKRODT
MERCK & CO
MYLAN NV
NEXTSOURCE BIOTECHNOLOGY LLC
NOVARTIS AG
OTSUKA HOLDINGS CO., LTD.
PFIZER INC.
SANOFI
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TORRENT PHARMACEUTICALS LTD.
UNITED THERAPEUTICS CORP.
UCB SA
CHAPTER 15 APPENDIX: ACRONYMS
CHAPTER 16 REFERENCES
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Neurological Disorders: Overview
Disease Background
Parkinson Disease
Alzheimer Disease
Schizophrenia
Bipolar Disorders
Depression
Epileptic Disorders
Autism Spectrum Disorders
Neuroprotective Agents
Neuroprotective Strategies
Drug Development Regulations
U.S.
Canada
Mexico
Europe
Asia-Pacific
ROW
Reimbursement Landscape
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Government and NGO Initiatives in Creating Awareness
Growing Geriatric Population with Neurological Disorders
Increasing Global Incidence of Neurological Disorders
Research Initiatives in Neurology
Accelerated Approvals for Drugs Used in Rare Diseases
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
Adverse Side Effects
High Cost of Drug Development
CHAPTER 5 GLOBAL MARKET FOR NEUROLOGY
Global Market for Neurology, by Disease Indication
CHAPTER 6 GLOBAL MARKET FOR PARKINSON DISEASE
Anti-Parkinson’s Drugs: Market Overview
Anti-Parkinson’s Drugs Market, by Drug Class
Dopaminergic
Market Size and Forecast
Market Analysis
Dopamine Agonists
Market Size and Forecast
Market Analysis
Enzyme Inhibitors Market
Market Size and Forecast
Market Analysis
Other Anti-Parkinson’s Drugs
Market Size and Forecast
Market Analysis
Anti-Parkinson’s Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
Global Company Share Analysis
CHAPTER 7 GLOBAL MARKET FOR ALZHEIMER DISEASE
Market Overview
Global Alzheimer Drugs Market, by Mechanism of Action
AChEIs
Market Size and Forecast
Market Analysis
NMDA Drugs
Market Size and Forecast
Market Analysis
Global Alzheimer Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Rest of the World
Market Size and Forecast
Market Analysis
Industry Structure
Impact of Generic AD Therapeutics
CHAPTER 8 GLOBAL MARKET FOR PSYCHOTIC DISORDERS
Market Overview
Global Antipsychotic Drugs Market, by Drug Class
D2 Antagonists
Market Size and Forecast
Market Analysis
D2/5HT2A Antagonists
Market Size and Forecast
Market Analysis
D2 Partial Agonists
Market Size and Forecast
Market Analysis
Global Antipsychotic Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
Global Company Share Analysis
Impact of Generic Antipsychotic Drugs on the Market
CHAPTER 9 GLOBAL MARKET FOR EPILEPTIC DISORDERS
Market Overview
Market Trends
Global Anti-Epileptic Drugs Market, by Drug Class
First Generation Anti-Epileptic Drugs
Market Size and Forecast
Market Analysis
Second Generation Anti-Epileptic Drugs
Market Size and Forecast
Market Analysis
Third Generation Anti-Epileptic Drugs
Market Size and Forecast
Market Analysis
Global Anti-Epileptic Drugs Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
Anti-Epileptic Drugs Market Competitive Landscape
CHAPTER 10 GLOBAL MARKET FOR AUTISM SPECTRUM DISORDERS
Market Overview
Antipsychotics
Antidepressants
Stimulants
Anticonvulsants
Global ASD Therapeutics Market, by Label Information
Labeled ASD Pharmaceuticals
Market Size and Forecast
Market Analysis
Off-label Pharmaceuticals
Market Size and Forecast
Market Analysis
Global ASD Therapeutics Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Rest of the World
Market Size and Forecast
Market Analysis
Global ASD Therapeutics Market Industry Structure
CHAPTER 11 GLOBAL MARKET FOR BRAIN TUMOR THERAPEUTICS
Market Overview
Brain Tumor Therapeutics Market, by Therapy Type
Chemotherapy
Market Size and Forecast
Market Analysis
Targeted Therapy
Market Size and Forecast
Market Analysis
Immunotherapy
Immunotherapeutic Agents
New Developments
Brain Tumor Therapeutics Market, by Region
North America
Market Size and Forecast
Market Analysis
Europe
Market Size and Forecast
Market Analysis
Asia-Pacific
Market Size and Forecast
Market Analysis
Rest of the World
Market Size and Forecast
Market Analysis
Company Share Analysis
CHAPTER 12 PIPELINE ANALYSIS
Overview of the Drug Development Process
CHAPTER 13 COMPETITIVE LANDSCAPE
Key Strategies Adopted by Market Players
Mergers and Acquisitions
Agreements and New Product Launches
CHAPTER 14 COMPANY PROFILES
ABBVIE
ACADIA PHARMACEUTICALS, INC.
ALEMBIC PHARMACEUTICALS LTD.
ALEXZA PHARMACEUTICALS
ALKERMES PLC
ALLERGAN PLC
APOTEX, INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
AUTISM THERAPEUTICS
AVANIR PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB CO.
BIOGEN
DAIICHI SANKYO CO., LTD.
DR. REDDY’S LABORATORIES LTD.
ELI LILLY AND CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GEDEON RICHTER PLC
IMMUNOCELLULAR THERAPEUTICS, LTD.
JOHNSON & JOHNSON
LANNETT CO., INC.
H. LUNDBECK A/S
LUPIN LTD.
MALLINCKRODT
MERCK & CO
MYLAN NV
NEXTSOURCE BIOTECHNOLOGY LLC
NOVARTIS AG
OTSUKA HOLDINGS CO., LTD.
PFIZER INC.
SANOFI
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TORRENT PHARMACEUTICALS LTD.
UNITED THERAPEUTICS CORP.
UCB SA
CHAPTER 15 APPENDIX: ACRONYMS
CHAPTER 16 REFERENCES
LIST OF TABLES
Summary Table: Global Market for Neurology, by Disease Indication, Through 2024
Table 1: Current Orphan Drugs Designations for Brain Tumors
Table 2: Global Market for Neurology, by Disease Indication, Through 2024
Table 3: Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2024
Table 4: Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2024
Table 5: Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2024
Table 6: Global Neurology Market for Alzheimer Drugs, by Region, Through 2024
Table 7: Global Ranking of Leading Players in Alzheimer’s Disease Drugs, by Company
Table 8: Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2024
Table 9: D2 Antagonist Drugs: Market Presence
Table 10: Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs
Table 11: Global Neurology Market for Antipsychotic Drugs, by Region, Through 2024
Table 12: Prevalence of Serious Mental Illness Among Adults in the U.S., by State, 2017
Table 13: Prevalence of Mental Illness in U.S., by Disease Indication, 2017
Table 14: Global Neurology Market for Anti-Epileptic Drugs, by Segment, Through 2024
Table 15: Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2024
Table 16: Global Neurology Market for ASD Therapeutics, by Label Information, Through 2024
Table 17: Selected Late-Stage Autism Treatments
Table 18: Global Neurology Market for ASD Therapeutics, by Region, Through 2024
Table 19: Global Market Ranking of Leading Players in ASD Drugs, by Company
Table 20: Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2024
Table 21: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
Table 22: Dosage and Administration of Temozolomide for Brain Tumors
Table 23: Current Brain Tumor Clinical Trials: Temozolomide
Table 24: Current Brain Tumor Clinical Trials Involving Lomustine
Table 25: Current Brain Tumor Clinical Trials involving Carmustine
Table 26: PCV Regimen: Brain Tumor Chemotherapy
Table 27: FDA Approved Targeted Therapeutic Agents for Brain Tumors
Table 28: Monoclonal Antibodies
Table 29: Small Molecule Monoclonal Antibodies
Table 30: Current Brain Tumor Clinical Trials Involving Bevacizumab
Table 31: Current Brain Tumor Clinical Trials Involving Everolimus
Table 32: Current Brain Tumor Clinical Trials: Immunotherapy
Table 33: Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2024
Table 34: Promising Forthcoming Neuroscience Therapies in Late Stage
Table 35: Agents Currently in Phase III of Alzheimer’s Disease Drug Development, 2018
Table 36: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
Table 37: Acronyms Used in This Report
Summary Table: Global Market for Neurology, by Disease Indication, Through 2024
Table 1: Current Orphan Drugs Designations for Brain Tumors
Table 2: Global Market for Neurology, by Disease Indication, Through 2024
Table 3: Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2024
Table 4: Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2024
Table 5: Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2024
Table 6: Global Neurology Market for Alzheimer Drugs, by Region, Through 2024
Table 7: Global Ranking of Leading Players in Alzheimer’s Disease Drugs, by Company
Table 8: Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2024
Table 9: D2 Antagonist Drugs: Market Presence
Table 10: Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs
Table 11: Global Neurology Market for Antipsychotic Drugs, by Region, Through 2024
Table 12: Prevalence of Serious Mental Illness Among Adults in the U.S., by State, 2017
Table 13: Prevalence of Mental Illness in U.S., by Disease Indication, 2017
Table 14: Global Neurology Market for Anti-Epileptic Drugs, by Segment, Through 2024
Table 15: Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2024
Table 16: Global Neurology Market for ASD Therapeutics, by Label Information, Through 2024
Table 17: Selected Late-Stage Autism Treatments
Table 18: Global Neurology Market for ASD Therapeutics, by Region, Through 2024
Table 19: Global Market Ranking of Leading Players in ASD Drugs, by Company
Table 20: Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2024
Table 21: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
Table 22: Dosage and Administration of Temozolomide for Brain Tumors
Table 23: Current Brain Tumor Clinical Trials: Temozolomide
Table 24: Current Brain Tumor Clinical Trials Involving Lomustine
Table 25: Current Brain Tumor Clinical Trials involving Carmustine
Table 26: PCV Regimen: Brain Tumor Chemotherapy
Table 27: FDA Approved Targeted Therapeutic Agents for Brain Tumors
Table 28: Monoclonal Antibodies
Table 29: Small Molecule Monoclonal Antibodies
Table 30: Current Brain Tumor Clinical Trials Involving Bevacizumab
Table 31: Current Brain Tumor Clinical Trials Involving Everolimus
Table 32: Current Brain Tumor Clinical Trials: Immunotherapy
Table 33: Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2024
Table 34: Promising Forthcoming Neuroscience Therapies in Late Stage
Table 35: Agents Currently in Phase III of Alzheimer’s Disease Drug Development, 2018
Table 36: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
Table 37: Acronyms Used in This Report
LIST OF FIGURES
Summary Figure: Global Market Share for Neurology, by Disease Indication, 2018
Figure 1: Pharmaceutical Regulatory Pathways in the U.S and Europe
Figure 2: Global Market for Neurology, by Disease Indication, 2018-2024
Figure 3: Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2018
Figure 4: Global Neurology Market for Dopaminergic Drugs, 2018-2024
Figure 5: Global Neurology Market for Dopamine Agonist Drugs, 2018-2024
Figure 6: Global Neurology Market for Enzyme Inhibitors Drugs, 2018-2024
Figure 7: Global Neurology Market for Other Anti-Parkinson’s Drugs, 2018-2024
Figure 8: Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2018
Figure 9: North American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 10: European Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 11: Asia-Pacific Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 12: South American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 13: Middle Eastern and African Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 14: Global Market Share for Key Competitors of Anti-Parkinson’s Drugs, 2018
Figure 15: Global Neurology Market for Alzheimer AChEIs Drugs, 2018-2024
Figure 16: Global Neurology Market for Alzheimer NMDA Drugs, 2018-2024
Figure 17: Global Neurology Market Share for Alzheimer Drugs, by Region, 2018
Figure 18: North American Neurology Market for Alzheimer Drugs, 2018-2024
Figure 19: European Neurology Market for Alzheimer Drugs, 2018-2024
Figure 20: Rest of the World Neurology Market for Alzheimer Drugs, 2018-2024
Figure 21: Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2018
Figure 22: Global Neurology Market for Antipsychotic Drugs in D2 Antagonist, 2018-2024
Figure 23: Global Neurology Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2018-2024
Figure 24: Global Neurology Market for Antipsychotic Drugs in D2 Partial Agonist, 2018-2024
Figure 25: Global Neurology Market Share for Antipsychotic Drugs, by Region, 2018
Figure 26: North American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 27: European Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 28: Asia-Pacific Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 29: South American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 30: Middle Eastern and African Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 31: Global Neurology Market Share for Antipsychotic Drugs, by Manufacturer, 2018
Figure 32: Global Neurology Market Share for Anti-Epileptic Drugs, by Segment, 2018
Figure 33: Global Neurology Market for First Generation Anti-Epileptic Drugs, 2018-2024
Figure 34: Global Neurology Market for Second Generation Anti-Epileptic Drugs, 2018-2024
Figure 35: Global Neurology Market for Third Generation Anti-Epileptic Drugs, 2018-2024
Figure 36: Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2018
Figure 37: North American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 38: European Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 39: Asia-Pacific Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 40: South American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 41: Middle Eastern and African Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 42: Global Neurology Market Share for Anti-Epileptic Drugs, by Manufacturer, 2018
Figure 43: Global Neurology Market Share for ASD Therapeutics, by Label Information, 2018
Figure 44: Global Neurology Market for Labeled ASD Drugs, 2018-2024
Figure 45: Global Neurology Market for Off-label Pharmaceuticals ASD, 2018-2024
Figure 46: Global Neurology Market Share for ASD Therapeutics, by Region, 2018
Figure 47: North American Neurology Market for ASD Therapeutics, 2018-2024
Figure 48: European Neurology Market for ASD Therapeutics, 2018-2024
Figure 49: Rest of the World Neurology Market for ASD Therapeutics, 2018-2024
Figure 50: Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2018
Figure 51: Global Neurology Market for Brain Tumor Chemotherapy, 2018-2024
Figure 52: Global Neurology Market for Brain Tumor Targeted Therapy, 2018-2024
Figure 53: Targeted Therapy Types
Figure 54: Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2018
Figure 55: North American Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 56: North American Incidence of Brain Tumors, 2018-2040
Figure 57: European Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 58: European Incidence of Brain Tumors, 2018-2040
Figure 59: Asia-Pacific Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 60: Asia-Pacific Incidence of Brain Tumors, 2018-2040
Figure 61: ROW Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 62: Shares of Major Players in Brain Tumor Therapeutics Market, 2018
Summary Figure: Global Market Share for Neurology, by Disease Indication, 2018
Figure 1: Pharmaceutical Regulatory Pathways in the U.S and Europe
Figure 2: Global Market for Neurology, by Disease Indication, 2018-2024
Figure 3: Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2018
Figure 4: Global Neurology Market for Dopaminergic Drugs, 2018-2024
Figure 5: Global Neurology Market for Dopamine Agonist Drugs, 2018-2024
Figure 6: Global Neurology Market for Enzyme Inhibitors Drugs, 2018-2024
Figure 7: Global Neurology Market for Other Anti-Parkinson’s Drugs, 2018-2024
Figure 8: Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2018
Figure 9: North American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 10: European Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 11: Asia-Pacific Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 12: South American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 13: Middle Eastern and African Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 14: Global Market Share for Key Competitors of Anti-Parkinson’s Drugs, 2018
Figure 15: Global Neurology Market for Alzheimer AChEIs Drugs, 2018-2024
Figure 16: Global Neurology Market for Alzheimer NMDA Drugs, 2018-2024
Figure 17: Global Neurology Market Share for Alzheimer Drugs, by Region, 2018
Figure 18: North American Neurology Market for Alzheimer Drugs, 2018-2024
Figure 19: European Neurology Market for Alzheimer Drugs, 2018-2024
Figure 20: Rest of the World Neurology Market for Alzheimer Drugs, 2018-2024
Figure 21: Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2018
Figure 22: Global Neurology Market for Antipsychotic Drugs in D2 Antagonist, 2018-2024
Figure 23: Global Neurology Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2018-2024
Figure 24: Global Neurology Market for Antipsychotic Drugs in D2 Partial Agonist, 2018-2024
Figure 25: Global Neurology Market Share for Antipsychotic Drugs, by Region, 2018
Figure 26: North American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 27: European Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 28: Asia-Pacific Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 29: South American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 30: Middle Eastern and African Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 31: Global Neurology Market Share for Antipsychotic Drugs, by Manufacturer, 2018
Figure 32: Global Neurology Market Share for Anti-Epileptic Drugs, by Segment, 2018
Figure 33: Global Neurology Market for First Generation Anti-Epileptic Drugs, 2018-2024
Figure 34: Global Neurology Market for Second Generation Anti-Epileptic Drugs, 2018-2024
Figure 35: Global Neurology Market for Third Generation Anti-Epileptic Drugs, 2018-2024
Figure 36: Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2018
Figure 37: North American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 38: European Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 39: Asia-Pacific Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 40: South American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 41: Middle Eastern and African Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 42: Global Neurology Market Share for Anti-Epileptic Drugs, by Manufacturer, 2018
Figure 43: Global Neurology Market Share for ASD Therapeutics, by Label Information, 2018
Figure 44: Global Neurology Market for Labeled ASD Drugs, 2018-2024
Figure 45: Global Neurology Market for Off-label Pharmaceuticals ASD, 2018-2024
Figure 46: Global Neurology Market Share for ASD Therapeutics, by Region, 2018
Figure 47: North American Neurology Market for ASD Therapeutics, 2018-2024
Figure 48: European Neurology Market for ASD Therapeutics, 2018-2024
Figure 49: Rest of the World Neurology Market for ASD Therapeutics, 2018-2024
Figure 50: Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2018
Figure 51: Global Neurology Market for Brain Tumor Chemotherapy, 2018-2024
Figure 52: Global Neurology Market for Brain Tumor Targeted Therapy, 2018-2024
Figure 53: Targeted Therapy Types
Figure 54: Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2018
Figure 55: North American Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 56: North American Incidence of Brain Tumors, 2018-2040
Figure 57: European Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 58: European Incidence of Brain Tumors, 2018-2040
Figure 59: Asia-Pacific Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 60: Asia-Pacific Incidence of Brain Tumors, 2018-2040
Figure 61: ROW Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 62: Shares of Major Players in Brain Tumor Therapeutics Market, 2018
